Is a complete IRD research report available?

No complete published report is available for Opus Genetics, Inc. (IRD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Opus Genetics, Inc. (IRD)

NASDAQ: IRD · USD

$3.68

+0.22 (+6.4%)· Recorded snapshot

Market cap	306.2M
Revenue (ttm)	9.9M
Net income (ttm)	-107.6M
EPS (ttm)	-$1.29
Shares out	83.2M
Volume	927,148
Beta	0.62

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 9.9M
Net income (ttm): -107.6M
EPS (ttm): -$1.29
Market cap: 306.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Metric	Value
Amount currency	USD
CIK code	0001228627
Company name	Opus Genetics, Inc.
Country	United States
Country code	US
CUSIP number	67577R102
Earnings date	2026-11-11
Earnings time	bmo
Employees	28
Employees change	10
Employees growth	55.56%
Enterprise value	$253.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US67577R1023
Last 10-K release date	2026-03-12
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$306.2M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$3.68
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	IRD
U.S. state	North Carolina
Website	https://opusgtx.com

Metric

Value

Amount currency

USD

CIK code

0001228627

Company name

Opus Genetics, Inc.

Country

United States

Country code

CUSIP number

67577R102

Earnings date

2026-11-11

Earnings time

bmo

Employees

Employees change

Employees growth

55.56%

Enterprise value

$253.6M

Exchange

NASDAQ

Financial currency

USD

Financial report date

2026-06-30

First seen

2026-05-09

Fiscal year end

December

Founded

2018

In index

RUSSELL2000

Industry

Biotechnology

Is primary listing

Yes

Is SPAC

ISIN number

US67577R1023

Last 10-K release date

2026-03-12

Last earnings date

2026-08-06

Last refreshed

2026-10-28

Last stock split type

Never

Market cap

$306.2M

Market cap category

Micro-Cap

Next earnings date

2026-11-11

Options

Yes

Price

$3.68

Price currency

USD

Sector

Healthcare

SIC code

2834

Stock price date

2026-10-28

Symbol

IRD

U.S. state

North Carolina

Website

https://opusgtx.com

Metric	Value
Earnings yield	-35.12%
EV/Sales	25.22x
FCF / EV yield	-16.36%
FCF yield	-13.5%
Forward EV/Sales	18.65x
Forward P/S	22.6x
P/S ratio	30.56x
Sector forward P/E	23.56x
Sector P/E	50.08x

Metric

Value

Earnings yield

-35.12%

EV/Sales

25.22x

FCF / EV yield

-16.36%

FCF yield

-13.5%

Forward EV/Sales

18.65x

Forward P/S

22.6x

P/S ratio

30.56x

Sector forward P/E

23.56x

Sector P/E

50.08x

Metric	Value
Gross margin	-291.85%
Operating margin	-513.47%
Pretax margin	-1,091.82%
Profit per employee	$-3.8M
Revenue per employee	$352,000
ROA	-48.06%
ROA (5Y)	-29.93%
ROCE	-59.29%
ROE	-4,796.52%
ROE (5Y)	-331.7%
ROIC	-70.88%
SBC / revenue	45.26%

Metric

Value

Gross margin

-291.85%

Operating margin

-513.47%

Pretax margin

-1,091.82%

Profit per employee

$-3.8M

Revenue per employee

$352,000

ROA

-48.06%

ROA (5Y)

-29.93%

ROCE

-59.29%

ROE

-4,796.52%

ROE (5Y)

-331.7%

ROIC

-70.88%

SBC / revenue

45.26%

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	-36.09%
Revenue growth (Q)	-73.8%
Revenue growth (QoQ)	-65%
Revenue growth 3Y	-39.84%
Revenue growth 5Y	150.46%
Revenue growth years	1

Metric

Value

EPS growth years

Net income growth years

Revenue growth

-36.09%

Revenue growth (Q)

-73.8%

Revenue growth (QoQ)

-65%

Revenue growth 3Y

-39.84%

Revenue growth 5Y

150.46%

Revenue growth years

Metric	Value
Depreciation and amortization	$53,000
EBIT	$-50.6M
EBITDA	$-50.6M
EPS	$-1.29
FCF per share	$-0.49
Financing cash flow	$97.2M
Free cash flow	$-40.7M
Free cash flow minus SBC	$-45.1M
Gross profit	$-28.8M
Net borrowing	$35M
Net cash flow	$56.5M
Net income	$-107.6M
Operating cash flow minus SBC	$-45.1M
Operating income	$-50.6M
Revenue	$9.9M
Stock-based compensation	$4.5M

Metric

Value

Depreciation and amortization

$53,000

EBIT

$-50.6M

EBITDA

$-50.6M

EPS

$-1.29

FCF per share

$-0.49

Financing cash flow

$97.2M

Free cash flow

$-40.7M

Free cash flow minus SBC

$-45.1M

Gross profit

$-28.8M

Net borrowing

$35M

Net cash flow

$56.5M

Net income

$-107.6M

Operating cash flow minus SBC

$-45.1M

Operating income

$-50.6M

Revenue

$9.9M

Stock-based compensation

$4.5M

Metric	Value
Altman Z-Score	-3.4
Book value per share	$-0.16
Interest coverage	-32.32
Long-term assets	$272,000
Long-term liabilities	$98.3M
Net cash (debt)	$52.6M
Net cash / market cap	17.47%
Net cash growth	67.39%
Piotroski F-Score	2
Property, plant and equipment	$172,000
Shareholders' equity	$-13M
Tangible book value	$-13M
Tangible book value per share	$-0.16
Total assets	$93M
Total cash	$88.8M
Total debt	$36.2M
Total liabilities	$106M
WACC	7.21%

Metric

Value

Altman Z-Score

-3.4

Book value per share

$-0.16

Interest coverage

-32.32

Long-term assets

$272,000

Long-term liabilities

$98.3M

Net cash (debt)

$52.6M

Net cash / market cap

17.47%

Net cash growth

67.39%

Piotroski F-Score

Property, plant and equipment

$172,000

Shareholders' equity

$-13M

Tangible book value

$-13M

Tangible book value per share

$-0.16

Total assets

$93M

Total cash

$88.8M

Total debt

$36.2M

Total liabilities

$106M

WACC

7.21%

Metric	Value
Asset turnover	0.15
Current assets	$92.7M
Current liabilities	$7.6M
Current ratio	12.19
Net working capital	$-3.7M
Quick ratio	11.87
Working capital	$85.1M
Working capital turnover	0.19

Metric

Value

Asset turnover

0.15

Current assets

$92.7M

Current liabilities

$7.6M

Current ratio

12.19

Net working capital

$-3.7M

Quick ratio

11.87

Working capital

$85.1M

Working capital turnover

0.19

Metric	Value
Buyback yield / dilution	-116.9%
Dividend yield	0%
Shareholder yield	-116.9%

Metric

Value

Buyback yield / dilution

-116.9%

Dividend yield

Shareholder yield

-116.9%

Metric	Value
150-day SMA	$4.36
1D price change	6.36%
1M price change	-25.53%
1M total return	-25.53%
1W price change	-11.6%
1W total return	-11.6%
1Y price change	77.25%
1Y return CAGR	77.32%
1Y total return	77.25%
20-day SMA	$4.09
200-day SMA	$4.17
3M price change	5.82%
3M total return	5.82%
3Y price change	28.44%
3Y return CAGR	8.7%
3Y total return	28.44%
50-day SMA	$4.48
50-day SMA vs 200-day SMA	50over200
52-week high	$7.07
52-week high date	2026-09-09
52-week low	$1.70
52-week low date	2025-11-18
5Y price change	-11.15%
5Y return CAGR	-2.34%
5Y total return	-11.15%
6M price change	-30.76%
6M total return	-30.76%
All-time high	$13.81
All-time high date	2021-02-03
All-time low	$0.65
All-time low date	2025-04-10
Average true range (ATR)	$0.34
Average volume	1.6M
Beta (1Y)	0.75
Beta (2Y)	0.64
Beta (5Y)	0.62
Change from 52-week high	-47.95%
Change from 52-week low	116.47%
Change from all-time high	-74.33%
Change from all-time low	445.38%
Change from open	7.92%
Day's gap	-1.45%
Dollar volume	$3.4M
High price	$3.68
Low price	$3.41
Monthly RSI	53.97
Open price	$3.41
Position in 52-week range	100%
Premarket change	0%
Premarket close	$3.46
Premarket price	$3.46
Previous close	$3.46
Price vs 150-day SMA	-18.77%
Price vs 20-day SMA	-13.33%
Price vs 200-day SMA	-14.93%
Price vs 50-day SMA	-20.94%
Relative volume	0.57
RSI	36.05
Sharpe ratio	1.04
Sharpe ratio (3Y)	0.41
Sharpe ratio (5Y)	0.27
Sortino ratio	1.89
Sortino ratio (3Y)	0.72
Sortino ratio (5Y)	0.5
Volume	927.1K
Weekly RSI	44.94
YTD price change	76.37%
YTD total return	76.37%

Metric

Value

150-day SMA

$4.36

1D price change

6.36%

1M price change

-25.53%

1M total return

-25.53%

1W price change

-11.6%

1W total return

-11.6%

1Y price change

77.25%

1Y return CAGR

77.32%

1Y total return

77.25%

20-day SMA

$4.09

200-day SMA

$4.17

3M price change

5.82%

3M total return

5.82%

3Y price change

28.44%

3Y return CAGR

8.7%

3Y total return

28.44%

50-day SMA

$4.48

50-day SMA vs 200-day SMA

50over200

52-week high

$7.07

52-week high date

2026-09-09

52-week low

$1.70

52-week low date

2025-11-18

5Y price change

-11.15%

5Y return CAGR

-2.34%

5Y total return

-11.15%

6M price change

-30.76%

6M total return

-30.76%

All-time high

$13.81

All-time high date

2021-02-03

All-time low

$0.65

All-time low date

2025-04-10

Average true range (ATR)

$0.34

Average volume

1.6M

Beta (1Y)

0.75

Beta (2Y)

0.64

Beta (5Y)

0.62

Change from 52-week high

-47.95%

Change from 52-week low

116.47%

Change from all-time high

-74.33%

Change from all-time low

445.38%

Change from open

7.92%

Day's gap

-1.45%

Dollar volume

$3.4M

High price

$3.68

Low price

$3.41

Monthly RSI

53.97

Open price

$3.41

Position in 52-week range

100%

Premarket change

Premarket close

$3.46

Premarket price

$3.46

Previous close

$3.46

Price vs 150-day SMA

-18.77%

Price vs 20-day SMA

-13.33%

Price vs 200-day SMA

-14.93%

Price vs 50-day SMA

-20.94%

Relative volume

0.57

RSI

36.05

Sharpe ratio

1.04

Sharpe ratio (3Y)

0.41

Sharpe ratio (5Y)

0.27

Sortino ratio

1.89

Sortino ratio (3Y)

0.72

Sortino ratio (5Y)

0.5

Volume

927.1K

Weekly RSI

44.94

YTD price change

76.37%

YTD total return

76.37%

Metric	Value
Float	64.7M
Float percentage	77.79%
Shares change (QoQ)	28.19%
Shares change (YoY)	116.9%
Shares held by insiders	7.66%
Shares held by institutions	58.64%
Shares outstanding	83.2M
Short % of float	20.11%
Short % of shares	15.64%
Short ratio	2.6 days

Metric

Value

Float

64.7M

Float percentage

77.79%

Shares change (QoQ)

28.19%

Shares change (YoY)

116.9%

Shares held by insiders

7.66%

Shares held by institutions

58.64%

Shares outstanding

83.2M

Short % of float

20.11%

Short % of shares

15.64%

Short ratio

2.6 days

Opus Genetics, Inc. (IRD)

Price

Financial snapshot

Fair-value bridge

Latest news · IRD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IRD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IRD

Frequently asked questions